Tivozanib
This targeted therapy is used to treat adults with relapsed or refractory advanced renal cell carcinoma (kidney cancer) after two or more prior treatments. It works by blocking VEGF receptors, which cuts off the blood supply that tumors need to grow and spread. It is taken as an oral capsule on a schedule of three weeks on and one week off.
分子量
454.9000 g/mol
LogP
4.00
TPSA
108.00 Ų
リピンスキーの五則
適合
治療領域
作用機序
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
2D構造
Cite this structure
Embed this structure
SMILES
COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
InChI
InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
Molecular Formula
C22H19ClN4O5
HBD / HBA
2 / 7
回転可能結合数
6
重原子数
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
This targeted therapy is used to treat adults with relapsed or refractory advanced renal cell carcinoma (kidney cancer) after two or more prior treatments. It works by blocking VEGF receptors, which cuts off the blood supply that tumors need to grow and spread. It is taken as an oral capsule on a schedule of three weeks on and one week off.
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Yes, Tivozanib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1289494. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9911830. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tivozanib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tivozanib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tivozanib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tivozanib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tivozanib"></drugfyi-drug>